Invasive Lobular Carcinoma: Symptoms, Diagnosis, and Treatment Options

Invasive lobular carcinoma (ILC), also referred to as infiltrating lobular carcinoma, originates in the milk‑producing lobules of the breast. Unlike many breast cancers, ILC often presents without palpable lumps, making early detection challenging.

ILC follows a distinct growth pattern compared to the more common invasive ductal carcinoma (IDC), affecting how it spreads through breast tissue and beyond.

Metastatic spread occurs when tumor cells disseminate beyond the primary site. In ILC, cancer originates in the lobules, infiltrates surrounding breast tissue, and may involve regional lymph nodes or distant organs.

In 2023, approximately 298,000 U.S. women were expected to receive a diagnosis of invasive breast cancer, with ILC accounting for roughly 10% of cases. (National Cancer Institute, 2024)

Because ILC rarely forms discrete masses, early stages may be asymptomatic. As the disease progresses, patients may notice subtle breast changes:

• thickening or hardening in a specific area
• swelling or a feeling of fullness in a particular region
• texture or skin changes, such as dimpling
• a newly inverted nipple
• alterations in breast size or shape

Additional signs can include:

• breast or nipple pain
• non‑milk discharge
• lump in the underarm area

These symptoms represent common early indicators of breast cancer, including ILC. Prompt evaluation by a healthcare professional is essential.

The precise etiology of ILC remains under investigation, but it typically arises from somatic mutations that disrupt the regulatory pathways governing cell proliferation and apoptosis within the lobular epithelium.

ILC cells tend to infiltrate in a single‑file, linear pattern, akin to branching, which contributes to its subtle presentation and makes lump detection difficult.

Several factors can increase the risk of developing ILC, including:

Lobular carcinoma in situ (LCIS)

A prior diagnosis of lobular carcinoma in situ (LCIS) elevates the risk of subsequent invasive lobular carcinoma. LCIS is characterized by atypical cells confined to the lobules without invasion into adjacent tissue.

While LCIS itself is not malignant, it is considered a marker of increased breast cancer susceptibility.

Diagnostic imaging for ILC typically involves mammography, breast MRI, and ultrasound. Radiologists look for subtle architectural distortions and asymmetries that may indicate lobular involvement.

Pathologic Subtypes

Pathologic subtyping of ILC is based on cytologic architecture. The classic form displays tumor cells arranged in single‑file lines.

Other less common variants include:

• Solid: cells grow in large sheets
• Alveolar: cells cluster in groups of 20 or more
• Tubulolobular: a mix of single‑file lines and tube‑like structures
• Pleomorphic: larger cells with heterogeneous nuclei
• Signet ring cell: cells filled with mucin

Mammography

ILC often lacks well‑formed masses or microcalcifications, making it difficult to distinguish from normal breast tissue on mammography.

Because ILC frequently presents as multifocal or bilateral disease, lesions may appear deceptively small or even occult on imaging.

Staging

Staging of ILC involves assessing tumor size, nodal involvement, and distant metastasis to determine disease extent.

• tumor diameter
• number of involved lymph nodes
• presence of distant metastases

ILC is classified from stage I to stage IV, mirroring the TNM staging system used for all breast cancers.

Metastatic ILC commonly involves the gastrointestinal tract, peritoneum, and reproductive organs.

Assessment of metastatic spread may include sentinel lymph node evaluation, liver function tests, and imaging studies such as CT or PET scans.

Treatment Overview

Optimal management of ILC is individualized based on stage, patient age, comorbidities, and tumor biology, typically combining surgery with systemic therapy.

Because of ILC’s infiltrative growth, selecting a surgeon experienced in lobular disease is critical to achieve adequate resection margins.

Evidence indicates that breast‑conserving surgery (lumpectomy) followed by radiation can offer survival outcomes comparable to mastectomy for early‑stage ILC.

Lumpectomy is appropriate when the tumor is limited and localized, involving excision of the lesion with surrounding normal tissue.

For multifocal or extensive disease, mastectomy may be advised to ensure complete removal.

Lymph node assessment may involve sentinel lymph node biopsy or axillary dissection, depending on nodal involvement.

Adjuvant therapies—radiation, endocrine treatment, or cytotoxic chemotherapy—are employed to minimize recurrence risk.

Complementary and Alternative Therapies

Complementary and alternative medicine (CAM) modalities may alleviate treatment‑related symptoms, though they are not curative for breast cancer.

Hormone‑based therapies often provoke hot flashes and night sweats, impacting quality of life.

Consultation with your oncology team is essential before initiating any new supplement or therapy, as interactions can alter efficacy or safety.

Endocrine therapy is indicated for hormone‑receptor‑positive ILC, blocking estrogen or progesterone signaling that drives tumor growth.

Because ILC is frequently estrogen‑receptor positive, endocrine agents effectively suppress hormone‑driven proliferation.

Risk Reduction and Prevention

Risk‑reducing strategies for ILC include lifestyle modifications, chemoprevention, and enhanced surveillance.

Following an LCIS diagnosis, chemopreventive agents such as tamoxifen or aromatase inhibitors can reduce subsequent invasive breast cancer risk.

When hormone replacement therapy (HRT) is prescribed, it should be at the minimal effective dose and for the shortest duration necessary.

For individuals with significant familial risk, prophylactic mastectomy may be considered.

Support Resources

Engaging with local or online support networks offers peer connection and shared coping strategies.

Patient support groups, counseling services, and oncology nurse navigators can provide emotional and practical assistance during treatment.

Early diagnosis and advances in treatment improve long‑term outcomes for ILC. Prognosis depends on factors such as:

• stage of disease
• tumor grade and subtype
• surgical margin status
• age
• overall health
• response to therapy